BioSpace News Archive

Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), today announced the closing of its upsized public offering of 2,927,267 American Depositary Shares (“ADSs”), which includes the full exercise of the underwriters’ option to purchase 381,817 additional ADSs, at a public offering price of $13.75 per ADS, for total gross proceeds of approximately $40.25 million,

NuVasive, Inc. announced the Company will release its fourth quarter and full year 2019 earnings results on Thursday, February 20, 2020 after the close of the market.

INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $238 Million with Approximately 42,100 TRx

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 8% in the company’s quarterly cash dividend, beginning in the first quarter of 2020

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2019. Total revenues for the fourth quarter of 2019 were $5.9 billion compared to $5.8 billion for the same period in 2018.

Waters Corporation announced fourth quarter 2019 sales of $716 million, which were flat as reported, compared to sales of $715 million for the fourth quarter of 2018.

AMDT Holdings, Inc. develops disruptive products to address existing and emerging needs in the extremity market. The clinical use of the SixFix™ Circular Fixation System began in January, 2020

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that the United States Patent and Trademark Office (USPTO) has granted the Company a new patent for methods of screening for anti-PVRIG antibodies that inhibit the binding of PVRIG with PVRL2

BioMotiv, a mission-driven drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from research institutions into therapeutics, and Bristol-Myers Squibb Company (NYSE: BMY) today announced the launch of Anteros Pharmaceuticals, a biotechnology company focused on developing a new class of drugs for fibrotic and other inflammatory diseases.

Synteract, an innovative CRO partnering with biotech and pharma companies to bring new medicines to market, has acquired Clindata’s human health biometrics division to meet market demand for more adaptable biometrics services solutions